Pankovitch S, Frohlich M, AlOthman B, Marciniuk J, Bernier J, Paul-Emile D
Chest. 2024; 167(3):736-745.
PMID: 39384100
PMC: 11882739.
DOI: 10.1016/j.chest.2024.09.031.
Min H, Payne S, Stride E
Pharm Res. 2024; 41(6):1139-1148.
PMID: 38755398
PMC: 11525259.
DOI: 10.1007/s11095-024-03706-1.
Brattsand R, Selroos O
Pharmaceuticals (Basel). 2024; 17(4).
PMID: 38675463
PMC: 11055149.
DOI: 10.3390/ph17040503.
Li H, Makatsoris C, Forbes B
J Control Release. 2024; 370:195-209.
PMID: 38641021
PMC: 11847494.
DOI: 10.1016/j.jconrel.2024.04.021.
Wu Y, Zhang J
J Transl Int Med. 2023; 11(1):26-29.
PMID: 37223614
PMC: 10202017.
DOI: 10.2478/jtim-2022-0073.
Low Peak Inspiratory Flow Rates are Common Among COPD Inpatients and are Associated with Increased Healthcare Resource Utilization: A Retrospective Cohort Study.
Clark B, Wells B, Saha A, Franchino-Elder J, Shaikh A, Donato B
Int J Chron Obstruct Pulmon Dis. 2022; 17:1483-1494.
PMID: 35791340
PMC: 9250781.
DOI: 10.2147/COPD.S355772.
High Prevalence of Suboptimal Peak Inspiratory Flow in Hospitalized Patients With COPD: A Real-world Study.
Mahler D, Demirel S, Hollander R, Gopalan G, Shaikh A, Mahle C
Chronic Obstr Pulm Dis. 2022; 9(3):427-438.
PMID: 35788259
PMC: 9448011.
DOI: 10.15326/jcopdf.2022.0291.
Evaluating Drug Deposition Patterns from Turbuhaler® in Healthy and Diseased Lung Models of Preschool Children.
Kannan R, Arey R, Przekwas A, Berlinski A, Singh N
J Pulm Med Respir Care. 2022; 4(1).
PMID: 35224564
PMC: 8871561.
approach in the development of inhaled drug products: Nanocrystal-based formulations with budesonide as a model drug.
Shi C, Ignjatovic J, Liu T, Han M, Cun D, duris J
Asian J Pharm Sci. 2021; 16(3):350-362.
PMID: 34276823
PMC: 8261257.
DOI: 10.1016/j.ajps.2020.12.001.
Prevalence and Associated Factors of Suboptimal Daily Peak Inspiratory Flow and Technique Misuse of Dry Powder Inhalers in Outpatients with Stable Chronic Airway Diseases.
Ding N, Zhang W, Wang Z, Bai C, He Q, Dong Y
Int J Chron Obstruct Pulmon Dis. 2021; 16:1913-1924.
PMID: 34188467
PMC: 8236256.
DOI: 10.2147/COPD.S311178.
Peak Inspiratory Flow Rate in COPD: An Analysis of Clinical Trial and Real-World Data.
Anderson M, Collison K, Drummond M, Hamilton M, Jain R, Martin N
Int J Chron Obstruct Pulmon Dis. 2021; 16:933-943.
PMID: 33883890
PMC: 8055277.
DOI: 10.2147/COPD.S291554.
Controller Inhalers: Overview of Devices, Instructions for Use, Errors, and Interventions to Improve Technique.
Gleeson P, Feldman S, Apter A
J Allergy Clin Immunol Pract. 2020; 8(7):2234-2242.
PMID: 32173505
PMC: 7987134.
DOI: 10.1016/j.jaip.2020.03.003.
The Confusing World of Dry Powder Inhalers: It Is All About Inspiratory Pressures, Not Inspiratory Flow Rates.
Clark A, Weers J, Dhand R
J Aerosol Med Pulm Drug Deliv. 2019; 33(1):1-11.
PMID: 31613682
PMC: 7041319.
DOI: 10.1089/jamp.2019.1556.
Does device matter for inhaled therapies in advanced chronic obstructive pulmonary disease (COPD)? A comparative trial of two devices.
Mannan H, Foo S, Cochrane B
BMC Res Notes. 2019; 12(1):94.
PMID: 30786914
PMC: 6383223.
DOI: 10.1186/s13104-019-4123-5.
Peak Inspiratory Flow Rate in Chronic Obstructive Pulmonary Disease: Implications for Dry Powder Inhalers.
Ghosh S, Ohar J, Drummond M
J Aerosol Med Pulm Drug Deliv. 2017; 30(6):381-387.
PMID: 28933581
PMC: 5915227.
DOI: 10.1089/jamp.2017.1416.
Personalization of Device Therapy - Prime Time for Peak Inspiratory Flow Rate.
Loh C, Ohar J
Chronic Obstr Pulm Dis. 2017; 4(3):172-176.
PMID: 28848928
PMC: 5556908.
DOI: 10.15326/jcopdf.4.3.2017.0155.
Routine Use of Budesonide/Formoterol Fixed Dose Combination in Elderly Asthmatic Patients: Practical Considerations.
Scichilone N, Braido F, Lavorini F, Levy M, Usmani O
Drugs Aging. 2017; 34(5):321-330.
PMID: 28258535
DOI: 10.1007/s40266-017-0449-7.
Aerosol Drug Delivery During Noninvasive Positive Pressure Ventilation: Effects of Intersubject Variability and Excipient Enhanced Growth.
Walenga R, Longest P, Kaviratna A, Hindle M
J Aerosol Med Pulm Drug Deliv. 2017; 30(3):190-205.
PMID: 28075194
PMC: 5467151.
DOI: 10.1089/jamp.2016.1343.
The Impact of Inspiratory Flow Rate on Drug Delivery to the Lungs with Dry Powder Inhalers.
Weers J, Clark A
Pharm Res. 2016; 34(3):507-528.
PMID: 27738953
DOI: 10.1007/s11095-016-2050-x.
Aerosolization, Drug Permeation and Cellular Interaction of Dry Powder Pulmonary Formulations of Corticosteroids with Hydroxypropyl-β-Cyclodextrin as a Solubilizer.
Vartiainen V, Bimbo L, Hirvonen J, Kauppinen E, Raula J
Pharm Res. 2016; 34(1):25-35.
PMID: 27604893
DOI: 10.1007/s11095-016-2035-9.